MRNA Sep 2024 100.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:26PM EDT. Market open.
| Previous close | 60.45 |
| Open | 52.62 |
| Bid | 52.60 |
| Ask | 54.60 |
| Strike | 100.00 |
| Expiry date | 2024-09-20 |
| Day's range | 52.62 - 52.62 |
| Contract range | N/A |
| Volume | |
| Open interest | 548 |
BenzingaModerna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
On Friday, Moderna Inc. (NASDAQ:MRNA) announced that it has submitted an FDA application for review of its Spikevax 2024-2025 formula, which targets the SARS-CoV-2 variant JN.1. The submission is based on FDA guidance, which advised that COVID-19 vaccines should be updated to a monovalent JN.1 composition for the 2024-2025 season. JN.1 and its descendants KP.2 and KP.3 are the versions of the virus that are most common in the U.S. right now, according to the US Centers for Disease Control and Pr
ZacksAcadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investor's Business DailyIs Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Moderna stock is on the rise amid a bevy of news, including FDA approval for its RSV vaccine. Is MRNA stock a buy right now?
© 2024 Yahoo. All rights reserved.